The available randomised controlled trials (RCTs) assessing the influence of peritoneal interposition flaps (PIF) on the reduction of symptomatic lymphoceles (sLCs) post robot-assisted radical prostatectomy (RARP) do not constitute a sufficient follow-up (FU) to assess the long-term effects. The PIANOFORTE trial was the first of these RCTs, showing no sLC reduction at the 3-month FU. Therefore, all 232 patients from the PIANOFORTE trial were invited for long-term FU. One hundred seventy-six patients (76%) presented themselves for FU and constituted the study group (SG). The median FU duration was 43 months. No significant differences in group allocation or LC endpoints at 90 days were observed between SG patients and patients not presenting themselves for the FU. During the FU period, four patients (2.3%) in the SG developed sLCs, and six patients (3.4%) developed asymptomatic lymphoceles (aLCs), which persisted in five patients (2.9%). There were no significant differences between PIF and non-PIF regarding sLC/aLC formation or persistence, newly developed complications, stress urinary incontinence or biochemical/clinical tumour recurrence. Therefore, this long-term FU confirms the primary outcomes of the PIANOFORTE trial that, while PIF does not impact complications or functionality, it does not reduce sLC/aLC rates. Furthermore, it shows the potential occurrence of LC after the third postoperative month.
目前评估腹膜间置瓣（PIF）对机器人辅助根治性前列腺切除术（RARP）后症状性淋巴囊肿（sLC）减少影响的随机对照试验（RCTs）随访时间不足，无法评估其长期效果。PIANOFORTE试验是其中首个RCT，其在3个月随访时未显示sLC减少。因此，PIANOFORTE试验的所有232名患者均被邀请进行长期随访。176名患者（76%）参与了随访，构成研究组（SG）。中位随访时间为43个月。在SG患者与未参与随访的患者之间，未观察到组别分配或90天时淋巴囊肿终点的显著差异。在随访期间，SG中有四名患者（2.3%）出现sLC，六名患者（3.4%）出现无症状淋巴囊肿（aLC），其中五名患者（2.9%）的淋巴囊肿持续存在。在sLC/aLC形成或持续、新发并发症、压力性尿失禁或生化/临床肿瘤复发方面，PIF组与非PIF组之间无显著差异。因此，这项长期随访证实了PIANOFORTE试验的主要结果：虽然PIF不影响并发症或功能，但并未降低sLC/aLC的发生率。此外，研究还显示术后第三个月后仍可能出现淋巴囊肿。
肿瘤(癌症)患者之家